← Human Trials & Peer-Reviewed Studies
The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes
Plain-language guide to PMID 29652465 (2016): clinical trial study of Insulin Glargine in 23 subjects, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 29652465
- Journal
- Srpski arhiv za celokupno lekarstvo
- Year
- 2016
- Study type
- Clinical Trial
- Authors
- Beljić-Živković T et al. (6 authors)
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at Insulin Glargine in the context of insulin resistance, prediabetes & type 2 diabetes.
Assessment of the effect of sitagliptin added to insulin glargine and metformin, in obese subjects with type 2 diabetes.
Why It Was Studied
A combination of drugs is required for treatment of obese subjects with diabetes, due to multiple pathogenic mechanisms implicated in the development of both diabetes and obesity.
Who Took Part
The study group was 23 subjects.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
A total of 23 obese subjects on metformin and insulin glargine participated in the study.
Body mass index, waist circumference, fasting, and prandial glucose were measured monthly, lipids and hemoglobin A1c (HbA1c) every three months, insulin, c-peptide and glucagon at the start and after six months of treatment.
How the Study Was Run
A time span of six months appears in the methods.
Homeostatic models for insulin secretion (HOMA B) and insulin resistance (HOMA IR) were calculated.
What Was Measured
The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Insulin Glargine, Insulin Resistance and Metformin.
What This Means in Plain Language
This is a clinical trial of Insulin Glargine in 23 subjects in people with insulin resistance, prediabetes & type 2 diabetes over six months.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2016 (Srpski arhiv za celokupno lekarstvo), a journal based in Serbia.
More context: the Insulin Glargine compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compound
Insulin Glargine: A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.